๐Ÿ“‹ Tables 93.8 & 93.11 ยท Opioid Prescribing & Adverse Effects

Nelson Textbook of Pediatrics 22nd Edition โ€” Chapter 93 | Table 93.11: Practical Aspects of Prescribing Opioids (pharmacology, equianalgesic dosing, tolerance vs dependence vs addiction) | Table 93.8: Management of Opioid-Induced Adverse Effects (respiratory depression, nausea, pruritus, constipation, urinary retention).

๐ŸŒ paeds.online โ€” Pakistan's Pediatric Platform

๐Ÿ“‹ Table 93.11 ยท Practical Aspects of Prescribing Opioids

PrincipleDetails
First-line opioids for severe painMorphine, hydromorphone, or fentanyl (IV/PO). Avoid meperidine (normeperidine toxicity).
TitrationDosing should be individualized. The right dose is the dose that relieves pain with acceptable side effects.
Caution in infantsLower clearance, prolonged half-life. Start with lower doses and monitor carefully.
Renal impairmentMorphine has active metabolite (M6G) that accumulates โ†’ toxicity. Fentanyl preferred in renal failure.
Hepatic impairmentReduce dose; monitor for sedation. Fentanyl is safest.
Equianalgesic doses (IV:PO)Morphine 1:3, Hydromorphone 1:3-4, Oxycodone N/A (PO only), Fentanyl 1:10 (oral transmucosal).
PCA (Patient-Controlled Analgesia)Basal rate + demand doses with lockout. For children โ‰ฅ5-6 years. Nurse-controlled for younger.
Tolerance vs Dependence vs AddictionTolerance: decreasing effect with continued use. Dependence: withdrawal upon abrupt cessation. Addiction: compulsive use despite harm (rare in children treated for pain).
Weaning opioidsAfter >1 week of use, taper gradually (e.g., 25% reduction per day) to prevent withdrawal.
Avoid codeine and tramadolFDA contraindicated in children <12 years (ultra-rapid metabolizers โ†’ respiratory depression).

๐Ÿ“‹ Table 93.8 ยท Management of Opioid-Induced Adverse Effects

Adverse EffectManagement
Respiratory depressionNaloxone 0.01-0.02 mg/kg IV/IM/IN (full reversal dose). For opioid-tolerant patients, use lower dose (0.001-0.005 mg/kg) to avoid withdrawal. Duration 1-4 hr; repeat as needed or start infusion.
Excessive sedation (no respiratory depression)Reduce opioid dose or change opioid. Consider methylphenidate or dextroamphetamine (palliative care).
Nausea and vomitingOndansetron 0.1 mg/kg IV (max 4 mg), metoclopramide, prochlorperazine. Change opioid if persistent.
PruritusDiphenhydramine 0.5 mg/kg PO/IV. Nalbuphine 0.1 mg/kg IV for epidural/intrathecal opioids. Low-dose naloxone infusion (0.5-2 mcg/kg/hr). Change opioid.
ConstipationProactive: stool softener (docusate) + stimulant (senna). Polyethylene glycol (MiraLAX). Methylnaltrexone (peripheral ฮผ-antagonist) for refractory cases.
Urinary retentionStraight catheterization, decrease opioid dose, consider naloxone infusion.
๐Ÿ’ก Naloxone dosing: For opioid-naive child with apnea/arrest: 0.01-0.02 mg/kg IV/IM. For chronic opioid therapy: start with 0.001-0.005 mg/kg to avoid withdrawal. Onset 1-2 min, duration 1-4 hr.

๐Ÿ“‹ 30 MCQs โ€” Opioid Prescribing & Adverse Effects

๐Ÿ“‡ Highโ€‘Yield Review Cards

๐Ÿฉบ Clinical Scenarios

Select a scenario for opioid management guidance.

๐Ÿ“‹ Stepwise Approach: Opioid Prescribing & Adverse Effect Management

    โšก Reflex Prompts โ€” Critical Opioid Decisions

    ๐Ÿ“– Summary: Opioid Prescribing & Adverse Effects โ€” Nelson Tables 93.8 & 93.11